InMed Pharmaceuticals Inc. (INM) Key Metrics
INM valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $7.3M
- Enterprise value
- $5.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 0.9
- Price / book
- 7.1
- EV / EBITDA
- 0.5
- Dividend yield
- —
- Beta
- 0.93
INM key metrics, FY2025–FY2026
Fiscal year ended June 30, 2026 · U.S. dollarsINM returns How much profit the business earns on the capital it uses.
INM financial health Debt, liquidity and how easily interest is covered.
INM efficiency & capital use Working capital cycle and where the cash goes.
INM valuation history
INM returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
INM debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
INM cash returned to shareholders
INM price vs earnings per share
INM key metrics
FY2025–FY2026| FY2026 | FY2025 | |
|---|---|---|
| Valuation | ||
| Market capitalization | $6.5M | — |
| Enterprise value | $4.2M | — |
| Price / sales | 0.0 | — |
| Price / book | 6.0 | — |
| EV / sales | 0.0 | — |
| Earnings yield | −194.6% | — |
| Free cash flow yield | −133,933.7% | — |
| Dividend yield | 6,688.8% | — |
| Shareholder yield (dividends + buybacks) | 6,688.8% | — |
| Share price at fiscal year-end | $1.55 | $3.25 |
| Per share | ||
| Revenue per share | $762.92 | — |
| Earnings per share | −$3.02 | — |
| Operating cash flow per share | −$2,075.97 | — |
| Free cash flow per share | −$2,075.97 | — |
| Cash per share | $0.54 | — |
| Book value per share | $0.26 | — |
| Tangible book value per share | $0.26 | — |
| Dividends per share | $103.68 | — |
| Capex per share | $0.00 | — |
| Shares outstanding | 4.2M | — |
| Returns & profitability | ||
| Return on equity (ROE) | −129.6% | −44.6% |
| Return on invested capital (ROIC) | — | −148.1% |
| Return on assets (ROA) | −103.6% | −38.5% |
| Return on tangible assets | −414.5% | −42.9% |
| Free cash flow margin | −272.1% | −157.1% |
| Financial health | ||
| Total debt | — | $1.0M |
| Cash & short-term investments | $2.2M | $15.1M |
| Net debt | −$2.2M | −$14.1M |
| Debt / equity | — | 0.06 |
| Debt / assets | — | 0.05 |
| Current ratio | 1.37 | 6.99 |
| Quick ratio | 1.37 | 6.47 |
| Interest coverage | -924.8 | -21.2 |
| Working capital | $721,646 | $15.0M |
| Invested capital | −$1.2M | $4.2M |
| Tangible asset value | $1.1M | $16.1M |
| Net current asset value | $721,646 | $14.6M |
| Graham net-net per share | $0.07 | — |
| Capital allocation | ||
| Dividends paid | $431.7M | — |
| Capex / revenue | 0.0% | 0.0% |
| Capex / depreciation | 0.00 | 0.00 |
| Stock-based compensation / revenue | 3.4% | 2.4% |
| R&D / revenue | 0.5% | 57.7% |
| SG&A / revenue | 59.2% | 132.7% |
| Efficiency | ||
| Days sales outstanding | — | 46.8 |
| Days of inventory on hand | — | 147.7 |
| Days payables outstanding | 0.1 | 56.9 |
| Cash conversion cycle (days) | — | 137.6 |
| Receivables turnover | — | 7.80 |
| Payables turnover | 3,446.34 | 6.42 |
| Inventory turnover | — | 2.47 |
| Asset turnover | 261.91 | 0.23 |
| Average receivables | — | $633,671 |
| Average payables | $715,731 | $504,292 |
| Average inventory | — | $1.3M |
| Intangibles / total assets | 0.0% | 10.4% |
Computed from INM's annual financial statements (latest annual report filed September 9, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
INM valuation and financial ratios
InMed Pharmaceuticals earned a return on equity of −129.6% in fiscal 2026. It returned $431.7 million to shareholders: $431.7 million in dividends and $0 in share buybacks.
See the INM income statement, the INM chart for price history, or the INM stock overview for the latest quote and news.
INM key metrics FAQ
What is InMed Pharmaceuticals's return on equity?
InMed Pharmaceuticals's return on equity (ROE) was −129.6% in fiscal 2026: net income of -$12.6 million on average shareholders' equity of $9.7 million.
What is InMed Pharmaceuticals's dividend yield?
InMed Pharmaceuticals paid $431.7 million in dividends in fiscal 2026 ($103.68 per share), a payout ratio of —.
What is InMed Pharmaceuticals's free cash flow yield?
InMed Pharmaceuticals generated -$8.6 billion of free cash flow in fiscal 2026, a free cash flow yield of −133,933.7% on its market value at year-end ($6.5 million).
What is InMed Pharmaceuticals's current ratio?
InMed Pharmaceuticals's current ratio was 1.37 at the end of fiscal 2026: current assets were 1.37 times current liabilities.